Pfizer Upgraded to Overweight; Goldman Downgrades Kimco to Sell

Here are today's top Wall Street analyst ratings where's unbiased fair value estimates support the recommendation.

Top Upgrades

  • Cantor Fitzgerald raised Cognizant Technology Solutions' (Nasdaq:CTSH) target price to $67 per share.'s fair value estimate is slightly lower at $66 per share implying 18% upside. ‘CTSH

  • Barclays upgraded Pfizer (NYSE:PFE) from Equal Weight to Overweight. Twelve valuation models suggest the stock is currently 15% undervalued. ‘PFE

  • Jefferies Group reiterated its Buy rating on AT&T (NYSE:T). Eleven valuation models imply a fair value of $45.50 per share representing 15% upside. ‘T

  • Citigroup upgraded Zimmer Biomet (NYSE:ZBH). The rating change is supported by the company's underlying fundamentals. ‘ZBH

Top Downgrades

  • Citigroup downgraded Science Applications International (NYSE:SAIC). Shares are currently trading at a 24% premium. ‘SAIC

  • KeyCorp downgraded Multi-Color Corp (Nasdaq:LABL) from Sector Weight to Underweight. Ten free cash flow models imply the stock is 20% overvalued.

  • Barclays downgraded Johnson & Johnson (NYSE:JNJ) from Overweight to Equal Weight. Fundamentals support the rating change. ‘JNJ

  • Goldman Sachs downgraded Kimco Realty (NYSE:KIM) from Neutral to Sell. Eight valuation models support the rating and conclude a negative 14% margin of safety. ‘KIM

Get Started Now!